Detection of chromosomal abnormalities in soft tissue sarcomas: Which sarcomas? Which abnormalities? How? Why?;Détection des anomalies chromosomiques et moléculaires dans les sarcomes des tissus mous: Quels sarcomes? Quelles anomalies? Comment? Pourquoi?

Bulletin du Cancer

Volumn 94, Issue 9, 2007, Pages 781-792

  Genevay, Muriel ^a   Gengler, Carole ^b   Guillou, Louis ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Genetics; RT PCR; Soft tissue sarcoma; Translocation

Indexed keywords

CANCER DIAGNOSIS; CARCINOGENESIS; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME MUTATION; CHROMOSOME TRANSLOCATION; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; HUMAN; MYXOSARCOMA; PROGNOSIS; REVIEW; RHABDOID TUMOR; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SOFT TISSUE TUMOR; SYNOVIAL SARCOMA; TUMOR GROWTH; CHROMOSOME ANALYSIS; CLASSIFICATION; FEMALE; GENETICS; MALE; METHODOLOGY; PATHOLOGY; SARCOMA;

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; MALE; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 35148865179     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0423     Document Type: Review

References (56)

1. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006 ; 48 : 13-21.
2. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003 ; 3 : 685-94.
3. Bridge JA, Sandberg AA. Cytogenetic and molecular genetic techniques as adjunctive approaches in the diagnosis of bone and soft tissue tumors. Skeletal Radiol 2000 ; 29 : 249-58.
4. Qian X, Jin L, Shearer BM, Ketterling RP, Jalal SM, Lloyd RV. Molecular diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor in formalin-fixed paraffin-embedded tissues by RT-PCR and fluorescence in situ hybridization. Diagn Mol Pathol 2005 ; 14 : 23-8.
5. Schleiermacher G, Peter M, Oberlin O, Philip T, Rubie H, Mechinaud F, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 2003 ; 21 : 85-91.
6. Avigad S, Cohen IJ, Zilberstein J, Liberzon E, Goshen Y, Ash S, et al. The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer 2004 ; 100 : 1053-8.
7. e éd. Paris : Flammarion Médecine-Sciences, 1993.
8. Hostein I, Pelmus M, Aurias A, Pedeutour F, Mathoulin-Pélissier S, Coindre JM. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material : a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J Pathol 2004 ; 202 : 95-102.
9. Coindre JM, Hostein I, Terrier P, Bouvier-Labit C, Collin F, Michels J, et al. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues. Cancer 2006 ; 107 : 1055-64.
10. Yamaguchi U, Hasegawa T, Morimoto Y, Tateishi U, Endo M, Nakatani F, et al. A practical approach to the clinical diagnosis of Ewing's sarcoma/primitive neuroectodermal tumour and other small round cell tumours sharing EWS rearrangement using new fluorescence in situ hybridization probes for EWSR1 on formalin-fixed, paraffin wax embedded tissue. J Clin Pathol 2005 ; 58 : 1051-6.
11. Folpe AL, Hill CE, Parham DM, O'Shea PA, Weiss SW. Immunohistochemical detection of FLi-1 protein expression : a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 2000 ; 24 : 1657-62.
12. Barnoud R, Sabourin JC, Pasquier D, Ranchere D, Bailly C, Terrier-Lacombe MJ, et al. Immunohistochemical expression of WT1 by desmoplastic small round cell tumor : a comparative study with other small round cell tumors. Am J Surg Pathol 2000 ; 24 : 830-6.
13. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions : a sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003 ; 27 : 750-61.
14. Bourdeaut F, Fréneaux P, Thuille B, Lellouch-Tubiana A, Nicolas A, Couturier J, et al. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol 2007 ; 211 : 323-30.
15. Evans HL. Low-grade fibromyxoid sarcoma : a report of two metastasizing neoplasms having a deceptively benign appearance. Am J Clin Pathol 1987 ; 88 : 615-9.
16. Mertens F, Fletcher C, Antonescu CR, Coindre JM, Colecchia M, Domanski HA, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest 2005 ; 85 : 408-15.
17. Guillou L, Benhattar J, Gengler C, Gallagher G, Ranchère-Vince D, Collin F, et al. Translocation-positive low-grade fibromyxoid sarcoma : clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma. A study from the French Sarcoma Group. Am J Surg Pathol 2007 ; (in press).
18. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors : from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003 ; 37 : 1-19.
19. Terrier-Lacombe MJ, Guillou L, Maire G, Terrier P, Vince DR, de Saint Aubain Somerhausen N, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children : clinicopathologic comparative analysis of 28 cases with molecular data - a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2003 ; 27 : 27-39.
20. In : Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization classification of tumors. Pathology and genetics of tumours of soft tissue and bone. Lyon : IARC Press, 2002.
21. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Liposarcoma. Cancer Genet Cytogenet 2004 ; 155 : 1-24.
22. Fagnou C, Michon J, Peter M, Bernoux A, Oberlin O, Zucker JM, et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. J Clin Oncol 1998 ; 16 : 1707-11.
23. Athale UH, Shurtleff SA, Jenkins JJ, Poquette CA, Tan M, Downing JR, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 2001 ; 23 : 99-104.
24. Kelly KM, Womer RB, Barr FG. Minimal disease detection in patients with alveolar rhabdomyosarcoma using a reverse transcriptase-polymerase chain reaction method. Cancer 1996 ; 78 : 1320-7.
25. Yaniv I, Cohen IJ, Stein J, Zilberstein J, Liberzon E, Atlas O, et al. Tumor cells are present in stem cell harvests of Ewings sarcoma patients and their persistence following transplantation is associated with relapse. Pediatr Blood Cancer 2004 ; 42 : 404-9.
26. West DC, Grier HE, Swallow MM, Demetri GD, Granowetter L, Sklar J. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol 1997 ; 15 : 583-8.
27. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett 2007 ; 254 : 1-10.
28. De Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998 ; 16 : 1248-55.
29. Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996 ; 14 : 1245-51.
30. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion : a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005 ; 23 : 548-58.
31. Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ, Deminiere C, Ranchere D, et al. Rhabdomyosarcoma : value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype. Cancer 2004 ; 101 : 2817-24.
32. Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2) (q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004 ; 64 : 5539-45.
33. Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006 ; 24 : 816-22.
34. Kelly KM, Womer RB, Sorensen PHB, Xiong QB, Barr FG. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 1997 ; 15 : 1831-6.
35. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma : a report from the Children's Oncology Group. J Clin Oncol 2002 ; 20 : 2672-9.
36. Thomson B, Hawkins D, Felgenhauer J, Radich JP. RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma. Bone Marrow Transplant 1999 ; 24 : 527-33.
37. Guillou L, Coindre JM, Gallagher G, Terrier P, Gebhard S, De Saint Aubain Somerhausen N, et al. Detection of the synovial sarcoma translocation t(X;18)(SYT;SXX) in paraffin-embedded tissues using reverse transcriptase- polymerase chain reaction : a reliable and powerful diagnostic tool for the pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum Pathol 2001 ; 32 : 105-12.
38. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma : a multi-institutional retrospective study of 243 patients. Cancer Res 2002 ; 62 : 135-40.
39. Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma : a multicenter, retrospective analysis. J Clin Oncol 2004 ; 22 : 4040-50.
40. Pedeutour F, Maire G, Sirvent N. De la cytogénétique à la cytogénomique des tumeurs adipocytaires. 2) Tumeurs adipocytaires malignes. Bull Cancer 2004 ; 91 : 317-23.
41. Pedeutour F, Fo C. De la cytogénétique à la cytogénomique des tumeurs adipocytaires. 1) Tumeurs adipocytaires bénignes. Bull Cancer 2002 ; 89 : 689-95.
42. Chibon F, Mariani O, Derre J, Mairal A, Coindre JM, Guillou L, et al. ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. Genes Chromosomes Cancer 2004 ; 40 : 32-7.
43. Binh MB, Sastre-Garau X, Guillou L, Pinieux GD, Terrier P, Lagace R, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes : a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005 ; 29 : 1340-7.
44. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization (FISH) in 200 paraffin-embedded tumor samples : utility in the differential diagnostic approach of adipocytic lesions and comparison with immunohistochemistry and real time PCR. Am J Surg Pathol 2007 ; (in press).
45. Coindre JM, Mariani O, Chibon F, Mairal A, De Saint Aubain Somerhausen N, Favre-Guillevin E, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas : a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol 2003 ; 16 : 256-62.
46. Coindre JM, Hostein I, Maire G, Derre J, Guillou L, Leroux A, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas : histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol 2004 ; 203 : 822-30.
47. Bui Nguyen Binh M, Guillou L, Hostein I, Chateau MC, Collin F, Aurias A, et al. Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk : clinicopathologic analysis of a series and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. Am J Surg Pathol 2007 ; (in press).
48. Rubin BP. Gastrointestinal stromal tumours : an update. Histopathology 2006 ; 48 : 83-96.
49. Miettinen M, Lasota J. Gastrointestinal stromal tumors : review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006 ; 130 : 1466-78.
50. Blay JY, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, et al. Recommandations pour la prise en charge des tumeurs stromales gastrointestinales (GIST). Bull Cancer 2005 ; 92 : 907-18.
51. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004 ; 22 : 3813-25.
52. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, Van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal tumours. Eur J Cancer 2006 ; 42 : 1093-103.
53. Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002 ; 8 : 3461-7.
54. Modena P, Lualdi E, Facchinetti F, Galli L, Teixeira MR, Pilotti S, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 2005 ; 65 : 4012-9.
55. Hornick JL, Dal Cin P, Fletcher CDM. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Mod Pathol 2007 ; 20 : 16A (abstr 52).
56. Cho YM, Choi J, Lee OJ, Lee HI, Jong D, Ro JY. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features. Pathol Int 2006 ; 56 : 702-6.